Case Reports

Treatment-related MDS/AML in a patient after treatment for large-cell neuroendocrine lung cancer


 

Secondary leukemia is a common late complication after exposure to cancer therapies such as chemotherapy and radiotherapy. With the increase in the overall survival of cancer patients over the past 3 decades, treatment-related malignant neoplasms have increased in incidence. Secondary leukemias due to breast cancer and Hodgkin lymphoma have been studied in detail, but to our knowledge only a few case studies have reported secondary leukemias with previous lung cancer.1-4 Lung cancer is the leading cause of cancer death in the United States.5

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Surgery, dose-escalated chemoradiotherapy yield similar outcomes in NSCLC
MDedge Hematology and Oncology
Commentary: Red meat and cancer risk – what your patients should know
MDedge Hematology and Oncology
Less pneumonitis with IMRT than 3D-CRT for non–small-cell lung cancer
MDedge Hematology and Oncology
Novel EGFR-TKI clears leptomeningeal disease in phase I study
MDedge Hematology and Oncology
Experimental LOXO-101 induces regression in several hard-to-treat cancers
MDedge Hematology and Oncology
Osimertinib approved for NSCLC
MDedge Hematology and Oncology
Pan-AKT inhibitor shrinks tumors in patients with AKT1 mutation
MDedge Hematology and Oncology
Balancing clinical and supportive care at every step of the disease continuum
MDedge Hematology and Oncology
Approval reinstates gefitinib as a therapy for lung cancer
MDedge Hematology and Oncology
Caregivers’ attitudes toward promoting exercise among patients with late-stage lung cancer
MDedge Hematology and Oncology